REAL-WORLD TREATMENT PERSISTENCE AMONG ADVANCED THERAPY-EXPERIENCED PATIENTS WITH ULCERATIVE COLITIS INITIATED ON USTEKINUMAB OR ADALIMUMAB

Maryia Zhdanava,Sumesh Kachroo,Porpong Boonmak,Sabree Burbage,Aditi Shah,Jill Korsiak,Patrick Lefebvre,Caroline Kerner,Dominic Pilon

DOI: https://doi.org/10.1093/ibd/izae020.080

2024-01-25

Inflammatory Bowel Diseases

Abstract:Abstract BACKGROUND Prior exposure to advanced therapies (ADT) is associated with reduced response to future therapies in patients with ulcerative colitis (UC). Therapy persistence is a proxy of real-world treatment performance. This study compared persistence among ADT-experienced patients with UC initiated on ustekinumab (anti-interleukin 12/23 antibody), or adalimumab (anti-tumor necrosis factor biologic). METHODS Adults with UC initiated on ustekinumab or adalimumab (index date) between 10/21/2019 and 03/02/2022 were selected from the IQVIA PharMetrics® Plus database. Patients were ADT-experienced (i.e., ≥1 claim for a non-index UC-indicated ADT) in the 12-month baseline period before the index date. Patients with other auto-immune diseases during the baseline period were excluded. Cohorts were balanced on baseline characteristics using inverse probability of treatment weights. Persistence was defined as the absence of gaps between days of therapy supply of >120 days for ustekinumab or >60 days for adalimumab. Composite endpoints of being persistent while on monotherapy (no immunomodulators or index ADT) and persistent while corticosteroid-free (<14 consecutive days of corticosteroid supply after day 90 post-index) were also assessed. Persistence endpoints were described post-maintenance phase until the earlier of 12 months, end of insurance eligibility, or data using weighted Kaplan-Meier analyses and weighted Cox proportional hazards models adjusted for the use of ≥2 biologics and class of biologics used pre-index. RESULTS There were 693 and 254 patients in the weighted ustekinumab versus adalimumab cohorts, respectively (Fig. 1). At 12 months after the maintenance phase start, 78.1% of the ustekinumab cohort and 59.2% of the adalimumab cohort were persistent on the index biologic; persistence was 2.44 times higher in the ustekinumab cohort relative to the adalimumab cohort (p-value: <0.001; Fig. 2a). Moreover, 66.7% of the ustekinumab cohort and 40.5% of the adalimumab cohort persisted on the index biologic while on monotherapy; persistence while on monotherapy was 2.53 times higher in the ustekinumab cohort relative to the adalimumab cohort (p-value: <0.001; Fig. 2b). Finally, 48.0% of the ustekinumab cohort and 42.8% of the adalimumab cohort were persistent while corticosteroid-free; persistence while corticosteroid-free was 1.24 times higher in the ustekinumab cohort relative to the adalimumab cohort (p-value 0.0447; Fig. 2c). CONCLUSIONS ADT-experienced patients with UC treated with ustekinumab were more persistent, including persistent while on monotherapy and while corticosteroid-free than patients treated with adalimumab. These findings may aid healthcare providers in choosing a biologic for ADT-experienced patients with UC. Figure 1 Selected baseline characteristics in weighted ustekinumab and adalimumab cohorts Figure 2 Persistence in weighted ustekinumab and adalimumab cohorts: a) persistent on index biologic, b) persistent and on monotherapy, c) persistent and corticosteroid-free

gastroenterology & hepatology

What problem does this paper attempt to address?

### Problems the Papers Try to Solve

#### The First Paper
**Background**:
- Patients with ulcerative colitis (UC) who have previously received advanced therapies (ADT) have a poorer response to future treatments.
- Treatment persistence is an important indicator for evaluating the actual treatment effect.

**Research Objectives**:
- To compare the treatment persistence of UC patients treated with ustekinumab (an anti - IL - 12/23 antibody) and adalimumab (an anti - tumor necrosis factor biologic).
- To pay special attention to the persistence during monotherapy and corticosteroid - free treatment.

#### The Second Paper
**Background**:
- Inflammatory bowel disease (IBD) is an important health burden in North America, but detailed data on different states, genders, and age groups in the United States are lacking.

**Research Objectives**:
- To systematically analyze the incidence, mortality, and disability - adjusted life years (DALYs) of IBD in the United States from 1999 to 2019, taking into account gender, age, and state - level differences.
- To explore the changing trends and geographical distribution characteristics of IBD during this period through the data of the Global Burden of Disease (GBD).

### Summary
The first paper aims to compare the treatment persistence of two different biologics in UC patients, especially for those who have already received other advanced therapies. The second paper systematically analyzes the epidemiological characteristics of IBD in the United States, including the changing trends of incidence, mortality, and DALYs, and explores the differences in these indicators among different genders, age groups, and states. Both papers provide important clinical and public health information, which is helpful for guiding medical decision - making and resource allocation.